ArriVent BioPharma (AVBP) Competitors $29.09 +0.07 (+0.24%) Closing price 04:00 PM EasternExtended Trading$29.08 -0.02 (-0.05%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends AVBP vs. DNLI, XENE, ACAD, VCEL, MOR, ZLAB, TWST, MLTX, CPRX, and MRUSShould you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include Denali Therapeutics (DNLI), Xenon Pharmaceuticals (XENE), ACADIA Pharmaceuticals (ACAD), Vericel (VCEL), MorphoSys (MOR), Zai Lab (ZLAB), Twist Bioscience (TWST), MoonLake Immunotherapeutics (MLTX), Catalyst Pharmaceuticals (CPRX), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry. ArriVent BioPharma vs. Denali Therapeutics Xenon Pharmaceuticals ACADIA Pharmaceuticals Vericel MorphoSys Zai Lab Twist Bioscience MoonLake Immunotherapeutics Catalyst Pharmaceuticals Merus ArriVent BioPharma (NASDAQ:AVBP) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends, earnings and community ranking. Do insiders and institutionals hold more shares of AVBP or DNLI? 9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 7.9% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor AVBP or DNLI? In the previous week, Denali Therapeutics had 1 more articles in the media than ArriVent BioPharma. MarketBeat recorded 8 mentions for Denali Therapeutics and 7 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.52 beat Denali Therapeutics' score of 0.51 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate AVBP or DNLI? ArriVent BioPharma presently has a consensus target price of $37.40, suggesting a potential upside of 28.90%. Denali Therapeutics has a consensus target price of $38.00, suggesting a potential upside of 58.70%. Given Denali Therapeutics' higher possible upside, analysts plainly believe Denali Therapeutics is more favorable than ArriVent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Denali Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.93 Is AVBP or DNLI more profitable? Denali Therapeutics' return on equity of -32.94% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -43.89% -29.67% Denali Therapeutics N/A -32.94%-30.04% Which has better valuation and earnings, AVBP or DNLI? ArriVent BioPharma has higher earnings, but lower revenue than Denali Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$69.33MN/AN/ADenali Therapeutics$330.53M10.43-$145.22M-$2.76-8.68 Does the MarketBeat Community prefer AVBP or DNLI? Denali Therapeutics received 441 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 68.15% of users gave Denali Therapeutics an outperform vote. CompanyUnderperformOutperformArriVent BioPharmaOutperform Votes17100.00% Underperform VotesNo VotesDenali TherapeuticsOutperform Votes45868.15% Underperform Votes21431.85% SummaryDenali Therapeutics beats ArriVent BioPharma on 9 of the 14 factors compared between the two stocks. Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVBP vs. The Competition Export to ExcelMetricArriVent BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$977.64M$6.90B$5.62B$9.11BDividend YieldN/A2.95%5.36%3.98%P/E RatioN/A10.0289.5017.56Price / SalesN/A348.161,227.7282.80Price / CashN/A65.0944.3037.67Price / Book-6.065.295.124.73Net Income-$69.33M$154.95M$117.78M$224.51M7 Day Performance6.48%3.10%1.92%-0.35%1 Month Performance7.66%3.17%11.12%4.91%1 Year Performance31.89%7.83%26.78%19.21% ArriVent BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVBPArriVent BioPharma1.1737 of 5 stars$29.09+0.2%$37.40+28.6%+45.8%$980.33MN/A0.0040Short Interest ↑DNLIDenali Therapeutics4.4947 of 5 stars$21.93+1.2%$38.91+77.4%+33.6%$3.16B$330.53M-7.95430Analyst ForecastShort Interest ↑XENEXenon Pharmaceuticals2.6652 of 5 stars$38.52-2.8%$56.00+45.4%-13.6%$2.94B$9.43M-13.66210Insider TradeAnalyst RevisionACADACADIA Pharmaceuticals3.9979 of 5 stars$17.57+0.3%$25.25+43.7%-33.3%$2.92B$726.44M22.53510Short Interest ↑Analyst RevisionVCELVericel2.3731 of 5 stars$59.07+4.8%$62.14+5.2%+32.4%$2.92B$197.52M984.66300Insider TradeMORMorphoSysN/A$18.96flat$18.25-3.7%N/A$2.86B$238.28M-5.45730ZLABZai Lab2.5225 of 5 stars$26.05+2.6%$55.00+111.1%+19.9%$2.85B$355.75M-9.402,175TWSTTwist Bioscience2.5942 of 5 stars$47.56+3.7%$51.90+9.1%+42.4%$2.82B$312.97M-13.21990Upcoming EarningsInsider TradeNews CoverageMLTXMoonLake Immunotherapeutics2.1502 of 5 stars$43.81+5.6%$84.29+92.4%-20.8%$2.80BN/A-33.962High Trading VolumeCPRXCatalyst Pharmaceuticals4.8603 of 5 stars$22.78+0.5%$32.86+44.2%+65.8%$2.72B$460.48M19.3180Short Interest ↑High Trading VolumeMRUSMerus3.0792 of 5 stars$39.45-0.5%$85.64+117.1%+17.6%$2.70B$35.93M-9.9937Short Interest ↓ Related Companies and Tools Related Companies Denali Therapeutics Competitors Xenon Pharmaceuticals Competitors ACADIA Pharmaceuticals Competitors Vericel Competitors MorphoSys Competitors Zai Lab Competitors Twist Bioscience Competitors MoonLake Immunotherapeutics Competitors Catalyst Pharmaceuticals Competitors Merus Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AVBP) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredDonald Trump is about to free crypto from its chains …On October 25th, Juan said Bitcoin would cross $100,000 before the inauguration. Now he thinks it could rea...Weiss Ratings | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredTrillion-Dollar Crypto PlayPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
